In breast cancer, PTEN inactivation, mainly through gene deletions, occurs in 5% of hormone receptor (HR) +/HER2- metastatic breast cancer (MBC) and leads to tumorigenesis and tumor progression [2]. This evidence concerns the gene PTEN and neoplasm.